Evidence map›Paper›PMID 30355350›Full record

ArticleBMC urology2018

Continuous saline bladder irrigation for two hours following transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer does not prevent recurrence or progression compared with intravesical Mitomycin-C.

Andrew T Lenis, Kian Asanad, Maher Blaibel, Nicholas M Donin, Karim Chamie

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC urology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Andrew T LenisDavid Geffen School of Medicine at the University of California Los Angeles, 300 Stein Plaza, Suite 348, Los Angeles, California, 90095, USA.ORCID http://orcid.org/0000-0001-9413-7793
Kian AsanadDavid Geffen School of Medicine at the University of California Los Angeles, 300 Stein Plaza, Suite 348, Los Angeles, California, 90095, USA.
Maher BlaibelRiverside School of Medicine, University of California, Riverside, California, USA.
Nicholas M DoninDavid Geffen School of Medicine at the University of California Los Angeles, 300 Stein Plaza, Suite 348, Los Angeles, California, 90095, USA.
Karim ChamieDavid Geffen School of Medicine at the University of California Los Angeles, 300 Stein Plaza, Suite 348, Los Angeles, California, 90095, USA. kchamie@mednet.ucla.edu.
University of California, Los Angeles · USUniversity of California, Riverside · US

Funding

NCI NIH HHS L30 CA154326
6 · The paper itself

Abstract

backgroundIntravesical Mitomycin-C (MMC) following transurethral resection of bladder tumor (TURBT), while efficacious, is associated with side effects and poor utilization. Continuous saline bladder irrigation (CSBI) has been examined as an alternative. In this study we sought to compare the rates of recurrence and/or progression in patients with NMIBC who were treated with either MMC or CSBI after TURBT.

methodsWe retrospectively reviewed records of patients with NMIBC at our institution in 2012-2015. Perioperative use of MMC (40 mg in 20 mL), CSBI (two hours), or neither were recorded. Primary outcome was time to recurrence or progression. Descriptive statistics, chi-squared analysis, Kaplan-Meier survival analysis, and Cox multivariable regression analyses were performed.

results205 patients met inclusion criteria. Forty-five (22.0%) patients received CSBI, 71 (34.6%) received MMC, and 89 (43.4%) received no perioperative therapy. On survival analysis, MMC was associated with improved DFS compared with CSBI (p = 0.001) and no treatment (p = 0.0009). On multivariable analysis, high risk disease was associated with increased risk of recurrence or progression (HR 2.77, 95% CI: 1.28-6.01), whereas adjuvant therapy (HR 0.35, 95% CI: 0.20-0.59) and MMC (HR 0.43, 95% CI: 0.25-0.75) were associated with decreased risk.

conclusionsPostoperative MMC was associated with improved DFS compared with CSBI and no treatment. The DFS benefit seen with CSBI in other studies may be limited to patients receiving prolonged irrigation. New intravesical agents being evaluated may consider saline as a control given our data demonstrating that short-term CSBI is not superior to TURBT alone.

Indexed as

Administration, IntravesicalAgedAged, 80 and overAntibiotics, AntineoplasticCombined Modality TherapyDisease-Free SurvivalDisease ProgressionFemaleFollow-Up StudiesHumansMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalProportional Hazards ModelsRetrospective StudiesAntibiotics, AntineoplasticMitomycinSaline SolutionBladder cancerMitomycin-COutcome assessmentRecurrenceTherapeutic irrigation

Identifiers

PMID30355350
PMCPMC6201555
OpenAlexW2898612486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.